ES2190487T3 - Nuevos agonistas y antagonistas del receptor de adenosina a1. - Google Patents

Nuevos agonistas y antagonistas del receptor de adenosina a1.

Info

Publication number
ES2190487T3
ES2190487T3 ES96945316T ES96945316T ES2190487T3 ES 2190487 T3 ES2190487 T3 ES 2190487T3 ES 96945316 T ES96945316 T ES 96945316T ES 96945316 T ES96945316 T ES 96945316T ES 2190487 T3 ES2190487 T3 ES 2190487T3
Authority
ES
Spain
Prior art keywords
antagonists
adenosine
new agonists
receiver
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96945316T
Other languages
English (en)
Inventor
Luiz Belardinelli
Ray Olsson
Stephen Baker
Peter J Scammells
Peter G Milner
Jurg R Pfister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Application granted granted Critical
Publication of ES2190487T3 publication Critical patent/ES2190487T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuesto que tiene la estructura: **(Fórmula)**
ES96945316T 1995-12-29 1996-12-26 Nuevos agonistas y antagonistas del receptor de adenosina a1. Expired - Lifetime ES2190487T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/581,655 US5736528A (en) 1993-10-28 1995-12-29 N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ES2190487T3 true ES2190487T3 (es) 2003-08-01

Family

ID=24326044

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96945316T Expired - Lifetime ES2190487T3 (es) 1995-12-29 1996-12-26 Nuevos agonistas y antagonistas del receptor de adenosina a1.

Country Status (15)

Country Link
US (2) US5736528A (es)
EP (1) EP1019426B1 (es)
JP (1) JP2000502712A (es)
KR (1) KR19990076916A (es)
CN (1) CN1163502C (es)
AT (1) ATE234322T1 (es)
AU (1) AU728439B2 (es)
BR (1) BR9612324A (es)
CA (1) CA2238736C (es)
DE (1) DE69626705T2 (es)
DK (1) DK1019426T3 (es)
ES (1) ES2190487T3 (es)
NZ (1) NZ326608A (es)
PT (1) PT1019426E (es)
WO (1) WO1997024363A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
MXPA03001741A (es) * 2000-09-08 2004-09-10 Cv Therapeutics Inc Ribosidos de purina como antiarritmicos.
CA2347879A1 (en) 2001-05-11 2002-11-11 Vanderbilt University Substituted dicinnamoylquinides and their use in augmentation of adenosine function
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
US20040121406A1 (en) * 2002-05-23 2004-06-24 Wilson Constance Neely Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
EA200500005A1 (ru) * 2002-06-12 2005-06-30 Байоджен Айдек Ма Инк. Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
TW200500070A (en) * 2003-04-25 2005-01-01 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
EP1932529A1 (en) 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
AU2005237466A1 (en) * 2004-04-16 2005-11-10 Novacardia, Inc. Combination therapy comprising an adenosine A1 receptor antagonist and an aldosterone inhibitor
US7781402B2 (en) * 2004-10-12 2010-08-24 Closed Loop Therapies Ltd. Methods and implantable devices for treating supraventricular arrhythmias
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
TWI653227B (zh) * 2014-07-11 2019-03-11 美商陶氏農業科學公司 用於製備４－（１－（４－（全氟乙氧基）苯基）－１ｈ－１，２，４－三唑－３－基）苯甲醯疊氮化物之改良方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics

Also Published As

Publication number Publication date
NZ326608A (en) 2000-04-28
US5736528A (en) 1998-04-07
AU1522097A (en) 1997-07-28
AU728439B2 (en) 2001-01-11
DK1019426T3 (da) 2003-07-14
DE69626705D1 (de) 2003-04-17
EP1019426A1 (en) 2000-07-19
EP1019426B1 (en) 2003-03-12
CN1163502C (zh) 2004-08-25
KR19990076916A (ko) 1999-10-25
WO1997024363A1 (en) 1997-07-10
CN1206420A (zh) 1999-01-27
CA2238736A1 (en) 1997-07-10
ATE234322T1 (de) 2003-03-15
CA2238736C (en) 2003-09-16
PT1019426E (pt) 2003-07-31
BR9612324A (pt) 1999-12-28
DE69626705T2 (de) 2003-09-18
US5998387A (en) 1999-12-07
JP2000502712A (ja) 2000-03-07

Similar Documents

Publication Publication Date Title
ES2190487T3 (es) Nuevos agonistas y antagonistas del receptor de adenosina a1.
DE69422191D1 (de) A1 adenosin rezeptor agonisten und antagonisten
ES2151652T3 (es) Derivados de indol como antagonistas del receptor 5ht.
WO1999064401A3 (en) Imidazolyl derivatives and their use as somatostatin receptor ligands
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
TR200103607T2 (tr) Pürin Türevleri
DE69719816T2 (de) N6-heterocyclisch substituierte Adenosin-Derivate
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
EA199800340A1 (ru) Производные пиримидина как антагонисты 5нт2с
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
BG106762A (en) Polycycloalkylpurines as adenosine receptor antagonists
ATE449076T1 (de) Imidazolderivate als histamin-h3-modulatoren
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
NO994850L (no) Farmakologiske midler
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
TR200301062T2 (tr) Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri
PE20010956A1 (es) Derivados de isoquinolina y quinazolina con afinidad por los receptores de serotonina combinados 5-ht1a, 5-ht1b, 5-ht1d
ES2120025T3 (es) Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
PT1200400E (pt) Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
ES2166462T3 (es) Antagonistas del receptor de la endotelina.
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
AU7319096A (en) Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation and their use as selective agonists of 5-ht1-like receptors
ES2196820T3 (es) Derivados de pirido(2,3-b)indolizina y aza-analogos de la misma; ligandos especificos de crf 1.